BIOA Insider Trading Activity and SEC Form 4 Filings
BIOA insider trading summary
Over the past 12 months, insiders at BioAge Labs, Inc. (BIOA) reported 13 sales worth $7.8M by 4 insiders and no open-market purchases on SEC Form 4. Net insider selling was $7.8M.
Latest BIOA insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Jun 30, 2026 | Shane Barton | Principal Accounting Officer | Sell | $509K (20,216 @ $25.19) |
| Jun 29, 2026 | Shane Barton | Principal Accounting Officer | Sell | $1.1M (42,350 @ $25.21) |
| Apr 1, 2026 | Paul D Rubin | Chief Medical Officer | Sell | $157K (8,820 @ $17.81) |
| Mar 2, 2026 | Paul D Rubin | Chief Medical Officer | Sell | $151K (7,433 @ $20.30) |
| Feb 2, 2026 | Paul D Rubin | Chief Medical Officer | Sell | $139K (7,433 @ $18.75) |
| Jan 13, 2026 | Dov A Md Goldstein | Chief Financial Officer | Sell | $41K (1,923 @ $21.08) |
| Jan 13, 2026 | Dov A Md Goldstein | Chief Financial Officer | Sell | $240K (11,663 @ $20.54) |
| Jan 13, 2026 | Kristen Fortney | Chief Executive Officer | Sell | $4.2M (233,107 @ $18.12) |
| Jan 13, 2026 | Dov A Md Goldstein | Chief Financial Officer | Sell | $165K (8,974 @ $18.43) |
| Jan 13, 2026 | Dov A Md Goldstein | Chief Financial Officer | Sell | $86K (4,440 @ $19.45) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.